Damaros Go back
From the founder

I started Damaros to make the distance between patient and trial, and the medical research behind it, smaller.

Anirudh C. Nimmagadda
Founder · MD, MSAI candidate
Why now

AI doesn't fix the bottleneck. It makes it worse.

AI is accelerating discovery across every form of clinical research, more candidates, more protocols, more amendments, tighter eligibility. None of it reaches a patient until a site executes. The constraint was never discovery. It is execution, and every model upstream multiplies the work downstream.

At major centers

More open protocols per coordinator, more amendments to re-screen against. Throughput stalls on the same manual eligibility work, just more of it.

At community sites

The patients are already there, but without an execution platform the matches are never seen in time. The gap between care and research only widens.

Across the pipeline

Candidates get surfaced, patients get enrolled, and the determination in between leaves no record.

More intelligence in the pipeline, across more protocols and more studies, makes a deterministic, replayable execution platform more necessary, not less.